OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.10
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio-15.31
Forward P/E Ratio-16.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 billion
Price / Sales2.33
Cash FlowN/A
Price / CashN/A
Book Value$3.37 per share
Price / Book1.32
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-308,870,000.00
Net Margins-31.27%
Return on Equity-8.76%
Return on Assets-6.50%
Miscellaneous
Employees6,030
Outstanding Shares559,470,000
OPKO Health (NASDAQ:OPK) Frequently Asked Questions
What is OPKO Health's stock symbol?
OPKO Health trades on the NASDAQ under the ticker symbol "OPK."
How were OPKO Health's earnings last quarter?
OPKO Health (NASDAQ:OPK) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.05. The biotechnology company had revenue of $254.90 million for the quarter, compared to the consensus estimate of $236.90 million. OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.06) EPS. View OPKO Health's Earnings History.
When is OPKO Health's next earnings date?
What price target have analysts set for OPK?
5 brokerages have issued twelve-month price objectives for OPKO Health's shares. Their forecasts range from $6.50 to $20.00. On average, they anticipate OPKO Health's stock price to reach $11.30 in the next twelve months. View Analyst Ratings for OPKO Health.
What are Wall Street analysts saying about OPKO Health stock?
Here are some recent quotes from research analysts about OPKO Health stock:
- 1. According to Zacks Investment Research, "OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. " (5/25/2018)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline." (5/9/2018)
- 3. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) On 01/12/18 OPK announces that GeneDx, Inc., a subsidiary of OPKO’s BioReference Laboratories, has entered into a research collaboration with the Nijmegen, Netherlands." (5/8/2018)
Are investors shorting OPKO Health?
OPKO Health saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 69,237,227 shares, an increase of 2.8% from the May 15th total of 67,373,455 shares. Based on an average trading volume of 6,672,224 shares, the short-interest ratio is currently 10.4 days. Currently, 21.3% of the company's stock are sold short.
Who are some of OPKO Health's key competitors?
Some companies that are related to OPKO Health include Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN) and Taro Pharmaceutical Industries (TARO).
Who are OPKO Health's key executives?
OPKO Health's management team includes the folowing people:
- Dr. Philip Frost, Chairman and Chief Exec. Officer (Age 82)
- Dr. Jane H. Hsiao Ph.D., MBA, Vice Chairman and Chief Technical Officer (Age 71)
- Mr. Adam E. Logal, Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer (Age 40)
- Mr. Steven D. Rubin, Exec. VP of Admin. and Director (Age 58)
- Ms. Kate Inman Esq., Deputy Gen. Counsel and Sec. (Age 45)
Has OPKO Health been receiving favorable news coverage?
Headlines about OPK stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OPKO Health earned a daily sentiment score of 0.10 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.85 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are OPKO Health's major shareholders?
OPKO Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.81%), Dimensional Fund Advisors LP (0.64%), Mackay Shields LLC (0.50%), Millennium Management LLC (0.39%), IFP Advisors Inc (0.38%) and UBS Group AG (0.35%). Company insiders that own OPKO Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for OPKO Health.
Which institutional investors are selling OPKO Health stock?
OPK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Guggenheim Capital LLC, Dimensional Fund Advisors LP, Ladenburg Thalmann Financial Services Inc., Burney Co., Cambridge Investment Research Advisors Inc., Teacher Retirement System of Texas and Royal Bank of Canada. View Insider Buying and Selling for OPKO Health.
Which institutional investors are buying OPKO Health stock?
OPK stock was acquired by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Millennium Management LLC, Intrinsic Edge Capital Management LLC, UBS Group AG, ETF Managers Group LLC, IFP Advisors Inc, Engineers Gate Manager LP and Asymmetry Capital Management L.P.. Company insiders that have bought OPKO Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for OPKO Health.
How do I buy shares of OPKO Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OPKO Health's stock price today?
One share of OPK stock can currently be purchased for approximately $4.44.
How big of a company is OPKO Health?
OPKO Health has a market capitalization of $2.46 billion and generates $1.07 billion in revenue each year. The biotechnology company earns $-308,870,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. OPKO Health employs 6,030 workers across the globe.
How can I contact OPKO Health?
OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for OPKO Health (OPK)
MarketBeat's community ratings are surveys of what our community members think about OPKO Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
